

NEONATAL Medication Monograph

ZIDOVUDINE

This document should be read in conjunction with this **DISCLAIMER**

Restricted: Requires Neonatologist/Microbiologist review within 24 hours of initiation

Zidovudine IV - SAS Category A (item requires approval by TGA)

Presentation	Vial: 200mg/20mL					
	Oral Liquid: 50mg/5mL					
Classification	Antiviral Medication					
Indication	Treatment and Prophylaxis for neonates born to HIV positive women					
Dose	Begin treatment within 4 hours of birth and continue for 4 weeks					
	Corrected Gestational Age	Route	Dose	Frequency		
	< 30 weeks	IV	1.5mg/kg/dose	Every 12 hours		
		Oral	2mg/kg/dose	Every 12 hours		
	30 to < 35 weeks	IV	1.5mg/kg/dose	Every 12 hours		
	Weeks	Oral	2mg/kg/dose	Every 12 hours for 2 weeks, Then every 8 hours for 2 weeks		
	≥ 35 weeks	IV	1.5mg/kg/dose	Every 6 hours		
		Oral	4mg/kg/dose	Every 12 hours		
		•	•			
Monitoring	Full Blood Picture and viral load (where indicated)					

Zidovudine - Neonatal Page 1 of 3

Guidelines &	HIV Prevention in Infants Born to HIV Positive Women			
Resources				
Compatible Fluids	Glucose 5%, Sodium Chloride 0.9%			
Preparation	<u>IV:</u>			
	Withdraw 1mL (10mg) of IV zidovudine and dilute to 5mL with compatible fluid			
	=10mg/5mL			
	Concentration = 2mg/mL			
Administration	Oral: May be given at any time with regards to feeds			
	IV: Infuse over 60 minutes			
Adverse Reactions	Anaemia, neutropenia, leucopoenia (IV doses/long term use)			
Storage	Store at room temperature – below 25°C			
	Protect from light.			
	Discard vial immediately after use.			
Interactions	IV: Meropenem			
Notes	If an infant vomits within 30 minutes of receiving an oral dose, the dose should be repeated.			
References	Truven Health Analytics. Zidovudine. In: NeoFax [Internet]. Greenwood Village (CO): Truven Health Analytics; 2020 [cited 2021 Feb 2]. Available from: https://neofax.micromedexsolutions.com/			
	Society of Hospital Pharmacists of Australia. Zidovudine. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2021 cited 2021 Feb 2]. Available from: http://aidh.hcn.com.au			

Document owner:	Head of Department - Neonatology					
Author / Reviewer:	KEMH & PCH Pharmacy / Neonatology Directorate					
Date first issued:	October 2013	Version:	3.1			
Last reviewed:	February 2021	Next review date:	February 2024			
Endorsed by:	Neonatal Directorate Management Group	Date:	February 2021			
Standards Applicable:	NSQHS Standards: 1 Governance 3 Infection Control 4 Medication Safety;					
Printed or personally saved electronic copies of this document are considered uncontrolled.						
Access the current version from the WNHS website.						

© Department of Health Western Australia 2020

Zidovudine - Neonatal Page 3 of 3